Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients

Drug Metabolism and Disposition

Volumn 37, Issue 4, 2009, Pages 821-826

  Hosohata, Keiko ^a   Masuda, Satohiro ^a   Katsura, Toshiya ^a   Takada, Yasutsugu ^b   Kaido, Toshimi ^b   Ogura, Yasuhiro ^b   Oike, Fumitaka ^b   Egawa, Hiroto ^b   Uemoto, Shinji ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; OMEPRAZOLE; TACROLIMUS;

ADULT; ALLELE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG METABOLISM; FEMALE; GENOTYPE; GRAFT RECIPIENT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IC 50; INTESTINE; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; WILD TYPE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; OMEPRAZOLE; TACROLIMUS;

EID: 63849162124     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.025833     Document Type: Article

References (39)

1. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9-28.
2. Christians U, Jacobsen W, Benet LZ, and Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41:813-851.
3. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, and Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836-847.
4. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, and Goldstein JA (1994a) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598.
5. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, and Goldstein JA (1994b) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419- 15422.
6. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41-49.
7. Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, Ogura Y, Oike F, Takada Y, Egawa H, et al. (2006) Population pharmacokinetic and pharmacogenomic analysis of tacroli-mus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80:331-345.
8. Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, et al. (2008) Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Phar-macogenet Genomics 18:413-423.
9. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, and Inui K (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14:471-478.
10. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, and Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154.
11. Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC, Malaise J, Lison D, and Mourad M (2006) CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 6:2706-2713.
12. Hebert MF (1997) Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27:201-214.
13. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, and van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
14. Hosohata K, Masuda S, Ogura Y, Oike F, Takada Y, Katsura T, Uemoto S, and Inui K (2008) Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet 23:134-138.
15. Inomata Y, Tanaka K, Egawa H, Uemoto S, Ozaki N, Okajima H, Satomura K, Kiuchi T, Yamaoka Y, and Hashida T (1996) The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 61:247-252.
16. Ishizaki T and Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 (Suppl 3):27-36.
17. Itagaki F, Homma M, Yuzawa K, Nishimura M, Naito S, Ueda N, Ohkohchi N, and Kohda Y (2004) Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthyvolunteers with CYP2C19 mutations. J Pharm Pharmacol 56:1055-1059.
18. Kahan BD, Keown P, Levy GA, and Johnston A (2002) Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 24:330-350; discussion 329.
19. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, and Wojnowski L (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374-1381.
20. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, and Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711-725.
21. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, and Sewing KF (1995) Metabolism of the immunosuppressant tacroli-mus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23:1315-1324.
22. Lapple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum M, and Kivisto KT (2003) Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 13:565-575.
23. Lecointre K, Furlan V, and Taburet AM (2002) In vitro effects of tacrolimus on human cytochrome P450. Fundam Clin Pharmacol 16:455-460.
24. Li XQ, Andersson TB, Ahlstrom M, and Weidolf L (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821-827.
25. Macphee IA, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, Goldberg L, and Holt DW (2005) Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 79:499-502.
26. Masuda S, Goto M, Fukatsu S, Uesugi M, Ogura Y, Oike F, Kiuchi T, Takada Y, Tanaka K, and Inui K (2006) Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther 79:90-102.
27. Masuda S and Inui K (2006) An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112:184-198.
28. Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, and Inui K (2004) Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin Pharmacol Ther 75:352-361.
29. Miura M, Inoue K, Kagaya H, Satoh S, Tada H, Sagae Y, Habuchi T, and Suzuki T (2007) Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos 28:167-175.
30. Obach RS, Zhang QY, Dunbar D, and Kaminsky LS (2001) Metabolic characterization of the major human small intestinal cytochrome P450s. Drug Metab Dispos 29:347-352.
31. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
32. Shimomura M, Masuda S, Goto M, Katsura T, Kiuchi T, Ogura Y, Oike F, Takada Y, Uemoto S, and Inui K (2008) Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. Drug Metab Pharmacokinet 23:313-317.
33. Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, Shimada T, and Funae Y (1994) Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 47:727-735.
34. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, and Inui K (2006) Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 16:119-127.
35. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, and Starzl T (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404-430.
36. Wang J, Zeevi A, McCurry K, Schuetz E, Zheng H, Iacono A, McDade K, Zaldonis D, Webber S, Watanabe RM, et al. (2006) Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 nonexpressors. Transpl Immunol 15:235-240.
37. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.
38. Yasuhara M, Hashida T, Toraguchi M, Hashimoto Y, Kimura M, Inui K, Hori R, Inomata Y, Tanaka K, and Yamaoka Y (1995) Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 27: 1108-1110.
39. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477-483.